Table 2.

Serum annexin A2 and α-fetoprotein levels in 241 patients with liver diseases (mean ± SD)

Group	n	(ng/mL)	q	P value	Pos. (%)	χ2	P value
ANXA2
HCC	115	24.60 ± 7.60			100 (86.96)1
MLC	25	24.22 ± 9.153	0.482	0.803	20 (80.00)3	0.812	0.368
LC	38	16.35 ± 8.863	11.621	< 0.001	12 (31.58)3	44.652	< 0.001
CH	35	6.85 ± 1.563	22.566	< 0.001	0 (0.00)3	91.304	< 0.001
AH	28	6.92 ± 1.413	20.948	< 0.001	0 (0.00)3	80.971	< 0.001
NC	30	6.16 ± 1.273	22.757	< 0.001	0 (0.00)3	84.058	< 0.001
AFP
HCC	115	1446.76 ± 1573.46			81 (70.44)2
MLC	25	1241.76 ± 1349.143	1.087	0.442	12 (48.00)3	4.635	0.031
LC	38	73.73 ± 168.033	7.969	< 0.001	6 (15.79)3	34.771	< 0.001
CH	35	69.05 ± 106.733	6.761	< 0.001	5 (14.29)3	34.583	< 0.001
AH	28	70.54 ± 107.113	7.306	< 0.001	4 (14.29)3	29.446	< 0.001
NC	30	6.06 ± 1.633	7.506	< 0.001	0 (0.00)3	47.874	< 0.001

¹Serum annexin A2 (ANXA2) level > 18 ng/mL or

²Serum α-fetoprotein (AFP) level > 50 ng/mL was abnormal;

³Compared with the hepatocellular carcinoma (HCC) group. MLC: Metastatic liver cancer; LC: Liver cirrhosis; CH: Chronic hepatitis; AH: Acute hepatitis; NC: Normal controls; Pos. (%): Positive case number (%).